Category Prostate Cancer

23
Aug

KCC Ranked as One of Best Cancer Hospitals in US

Men’s Health magazine recently ranked the Kimmel Cancer Center at Jefferson among the best in the nation, calling out its success in treating prostate cancer, a leading cancer in men. The American Cancer Society estimates there will be more than 1.5 million new cancer diagnoses in 2013. Jefferson scientist, Matthew Schiewer, Ph.D., recently received the Prostate Cancer Benjamin …

18
Jun

KCC Investigator wins Prostate Cancer Foundation Benjamin Franklin Young Investigator Award

Matthew Schiewer, PhD, a postdoctoral fellow in Dr. Karen Knudsen’s lab in the Department of Cancer Biology, is the recent recipient of a Prostate Cancer Foundation Young Investigator Award. Dr. Schiewer’s investigations will focus on the role of PARP-1 in DNA damage repair and the inhibition of PARP with specific medications as a potential therapy …

12
Feb

Jefferson Radiation Oncology Resident Looks to Improve Prostate Cancer Outcomes in Ghana

A new study published in January in the journal BMC Cancer, led by Kosj Yamoah, M.D., Ph.D., a resident in the Department of Radiation Oncology at Thomas Jefferson University and Hospital, takes aim at the issue by investigating prostate cancer diagnoses and treatment delivery in black men living in the West African region, in order …

21
Dec

Game changing diagnostic & prognostic prostate cancer genetic tests revealed by KCC researchers

Researchers at the Kimmel Cancer Center at Jefferson (KCC) have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers. The team, led by Richard G. Pestell, M.D., Ph.D., Director of the KCC and the Chair of the Department of Cancer Biology at Thomas Jefferson …

21
Dec

KCC researchers discover new pathways that drive metastatic prostate cancer

Elevated levels of Cyclin D1b could function as a novel biomarker of lethal metastatic disease in prostate cancer patients, according to a pre-clinical study published ahead of print on December 21 in the Journal of Clinical Investigation by researchers at the Kimmel Cancer Center at Jefferson. The group, headed by Karen E. Knudsen, Ph.D., Professor …

16
Oct

Stat5 Predicts Outcomes for Prostate Cancer Patients after Radical Prostatectomy

Men who had high levels of the activated Stat5 protein in their prostate cancer after a radical prostatectomy were more likely to have a recurrence or die from the disease compared to men who had little to no presence of the growth protein, according to a recent study published in Human Pathology by Jefferson’s Kimmel …

9
Oct

Doubling up on Advanced Prostate Cancer with PARP Inhibitors

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson’s Kimmel Cancer Center researchers suggests. The team, led by Karen E. Knudsen, Ph.D., Professor in the Departments of Cancer Biology, Urology, & Radiation Oncology at …

14
Sep

Jefferson and the Eagles Team Up for Prostate Health and Cancer Awareness

September is Prostate Cancer Awareness month, and Thomas Jefferson University Hospitals has again teamed up with the Philadelphia Eagles to educate fans and others about prostate health and to raise cancer awareness. To help kick off the campaign, Jefferson will serve as the presenting partner at the Sunday, September 16 game versus the Baltimore Ravens, with …

7
Sep

Dr. Karen Knudsen Led Group Receives Million Dollar Prostate Cancer Foundation Award

A group of investigators led by Dr. Karen Knudsen was awarded a 2-year challenge grant of one million dollars by the Prostate Cancer Foundation.  The details of this award (from the PCF web site) are: 2012 Movember-PCF Challenge Award Lead Investigator: Karen Knudsen, PhD Thomas Jefferson University Title Interrogation of Aberrant DNA Repair in Sporadic …

31
May

ASCO: Liver Metastases and its Prognostic Significance in Men With Metastatic Castration-Refractory Prostate Cancer

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655, Sunday, June 3, 8:00 AM – 12:00 PM CST, S Hall A2). In a phase III trial, lead study author William …

23
May

Data Continues to Support Provenge’s Overall Survival Benefit in Prostate Cancer Patients

This article was adapted from an OncLive story posted on May 21, 2012. Leonard G. Gomella, M.D, chair of the Department of Urology at Thomas Jefferson University Hospital and director of Clinical Affairs, Jefferson’s Kimmel Cancer Center, was part of the team to present new findings from the IMPACT trial looking at the immunotherapy sipuleucel-T …

16
May

Jefferson Receives $2.6 Million NIH Grant to Study Imaging Method to Stage Prostate Cancer Without Biopsy

Jefferson’s Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can …

29
Mar

Dr. Leonard Gomella, Program Director for IPCC in New York

Leonard G. Gomella, M.D., FACS, Chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center at Jefferson, will serve as the Program Director for the Fifth Annual Interdisciplinary Prostate Cancer Congress (IPCC) at the New York Marriott East Side in New York City on March 31. This …

22
Feb

PCF Young Investigator Award Goes to Jefferson Researcher

Heather Montie, Ph.D., a post-doctoral research fellow in the Department of Biochemistry and Molecular Biology, has received a Prostate Cancer Foundation Young Investigator Award for her work with androgen receptor (AR) acetylation and its role in castration-resistant prostate cancer. Young Investigator awards are designed to promote long-term careers in the field of prostate cancer by …

13
Feb

Curry spice component may help slow prostate tumor growth

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson’s Kimmel Cancer Center suggests. Reporting in a recent issue of Cancer Research, Karen Knudsen, Ph.D., a Professor of Cancer Biology, Urology and Radiation …

8
Feb

2011 Men’s Event Benefiting Prostate Cancer Research and patient care at Jefferson’s Kimmel Cancer Center

On Tuesday, November, 17th 2011, the Kimmel Cancer Center at Jefferson held the Third Annual Men’s Event benefiting prostate cancer research and patient care at the Prime Rib Restaurant in Philadelphia. The Men’s Event was emceed by Philadelphia Eagles Longsnapper, motivational speaker and magician, Jon Dorenbos. Receiving the Symbol of Courage was John Beuhler, prostate …

26
Jan

Brachytherapy reduced death rates in high-risk prostate cancer patients, study finds

Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise. A population-based analysis looking at almost 13,000 cases revealed that men who received brachytherapy alone or in combination with external beam radiation therapy (EBRT) had …

16
Jan

New Clinical Trial: Cabazitaxel with Radiation and Hormone Therapy May Improve Prostate Cancer Survival

Jefferson’s Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients. The single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel …

14
Oct

Ulrich Rodeck receives Ben Franklin-PCF Creativity Award

Ulrich Rodeck, M.D., Ph.D., a professor in the Department of Dermatology and Cutaneous Biology, at Jefferson Medical College, Thomas Jefferson University, received the Ben Franklin-Prostate Cancer Foundation Creativity award for his work in improving the therapeutic window of radiation therapy for prostate cancer. Radiation therapy of locally advanced prostate cancer is associated with severe toxicity …

29
Sep

Kimmel Cancer Center at Jefferson Celebrates 20 Years of Patient Care and Cancer Discovery

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who’ve provided an invaluable contribution to medical science and healthcare. “This is truly a milestone for the Kimmel Cancer Center—it’s …

Page 2 of 4